Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
K Hori, S Saito, K Hori, S Saito
Abstract
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an irreversible stasis of tumour blood flow (TBF) and subsequent loss of nutrient supply to tumour tissue. Since early 2002, under the new designation AVE8062, AC7700 has undergone clinical trials in Europe and the US. Questions remain, however, concerning how AC7700 blocks TBF and why the TBF stasis does not recover. In this study, using a rat tumour LY80, a variant of Yoshida sarcoma, we examined whether TBF cessation after AC7700 administration is due to a direct action of the agent on tumour blood vessels. We constructed electrodes that can drop a small quantity of the drug solution directly at the site of blood flow measurement and inserted them subcutaneously and into the tumour. We compared the blood flow responses of normal vessels and tumour vessels after administration of 10-microl doses of various concentrations (0.2, 1, 10, and 50 mg ml(-1)) of the AC7700 solution. In addition, we assessed TBF stasis after i.v. and intra-arterial 10 mg x kg(-1) AC7700 administration in an LY80-induced kidney tumour. To determine why the TBF stasis is irreversible, we observed AC7700-induced changes in host arterioles and the tumour vascular network of the Sato lung carcinoma using a vital microscopic rat transparent chamber. Since an increase in tumour interstitial fluid pressure brings about a decrease in TBF, we also measured 10 mg x kg(-1) AC7700-induced changes in this pressure. The sensitivity of the blood flow response after intratumoral application of AC7700 was markedly higher in normal vessels relative to tumour vessels. Intra-arterial administration of AC7700 did not have stronger effects on TBF stasis than did i.v. administration. Intravital microscopy showed that AC7700 induced a powerful and long-lasting constriction of host arterioles, so that complete stasis of blood flow occurred in downstream vessels, which supplied blood to tumours. Owing to this stasis, the lumens of numerous tumour vessels narrowed or completely disappeared, and numerous erythrocytes stagnated in drainage vessels of the tumour vascular network. Haemolysis of these erythrocytes occurred after 2-3 h, resulting in complete thrombosis. There was no indication of reperfusion in vessels showing haemolysis. This haemolysis is thought to be the main cause for the irreversibility of TBF stasis. Since the tumour interstitial fluid pressure decreased after i.v. AC7700 administration, the possibility of stasis of TBF being caused by tumour vascular compression was excluded. All these results strongly suggest that the main target of AC7700 is host arterioles and that the stasis of TBF induced by AC7700 is not triggered by a direct action of the drug on tumour vessels.
Figures
References
- Aukland K, Bower BF, Berliner RW (1964) Measurement of local blood flow with hydrogen gas. Circ Res 14: 164–187
- Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761–1767
- Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, Longo DL (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 53: 2204–2207
- Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829–1834
- Dowlati A, Robertson K, Cooney M, Petrons WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408–3416
- Eikesdal HP, Landuyt W, Dahl O (2002) The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4 An rat gliomas. Cancer Lett 178: 209–217
- Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318–1327
- Gullino PM, Clark SH, Grantham PH (1964) The interstitial fluid of solid tumor. Cancer Res 24: 780–797
- Gullino PM, Grantham FH (1961) Studies on the exchange of fluids between host and tumor. I. A method for growing ‘tissue-isolated’ tumors in laboratory animals. J Natl Cancer Inst 27: 679–693
- Hatanaka T, Fujita K, Ohsumi K, Nakagawa R, Fukuda Y, Nihei Y, Suga Y, Akiyama Y, Tsuji T (1998) Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg Med Chem Lett 8: 3371–3374
- Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90: 1026–1038
- Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86: 1604–1614
- Hori K, Saito S, Sato Y, Kubota K (2001) Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 7: 26–33
- Hori K, Suzuki M, Abe I, Saito S (1986) Increased tumor tissue pressure in association with the growth of rat tumors. Jpn J Cancer Res 77: 65–73
- Hori K, Suzuki M, Abe I, Saito S, Sato H (1981) New technique for measurements of microvascular pressure in normal and tumor vessels of rats. Invas Metast 1: 248–260
- Hori K, Suzuki M, Tanda S, Saito S (1990) In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81: 279–288
- Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang Q-H (1991) Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn J Cancer Res 82: 1309–1316
- Hori K, Zhang Q-H, Li H-C, Saito S (1995) Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow. Br J Cancer 71: 1163–1168
- Hori K, Zhang Q-H, Li H-C, Saito S, Sato Y (1996) Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int J Cancer 65: 360–364
- Hori K, Zhang Q-H, Saito S, Tanda S, Li H-C, Suzuki M (1993) Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res 53: 5528–5534
- Horsman MR, Ehrnrooth E, Ladekari M, Overgaard J (1998) The effect of combretastatin A-4 disodium phosphate in a C3 H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42: 895–898
- Jain RK (1987) Transport of molecules across tumor vasculature. Cancer Metast. Rev 6: 559–593
- Konerding MA, Steinberg F, Streffer C (1989) The vasculature of xenotransplanted human melanomas and sarcomas on nude mice. II. Scanning and transmission electron microscopic studies. Acta Anat 136: 27–33
- Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anne J, van Oosterom A, Lambin P (2000) Vascular targeting of solid tumours: a major ‘inverse’ volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36: 1833–1843
- Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE (2001) Combretastatin A-4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7: 1052–1060
- Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985–1000
- Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T (1999a) A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 90: 1016–1025
- Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y (1999b) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90: 1387–1395
- Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61: 711–716
- Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T (1998) Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 41: 3022–3032
- Papadimitriou JM, Woods AE (1975) Structural and functional characteristics of the microcirculation in neoplasms. J Pathol 116: 65–72
- Paskins-Hurlburt AJ, Hollenberg NK, Abrams HL (1982) Tumor perfusion in relation to the rapid growth phase and necrosis: studies on the Walker carcinoma in the rat testicle. Microvasc Res 24: 15–24
- Peterson H-I (1979) Tumor blood flow compared with normal tissue blood flow. In Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors, Peterson H-I (ed) pp 103 – 114 Boca Raton, FL: CRC Press
- Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209–211
- Pettit GR, Temple Jr C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322 Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299–309
- Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, Jain RK (1991) Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 51: 6695–6698
- Scholander PF, Hargens AR, Miller SL (1968) Negative pressure in the interstitial fluid of animals. Science 161: 321–328
- Simionescu M, Simionescu N (1984) Ultrastructure of the microvascular wall: functional correlations. In Handbook of Physiology Section 2: Cardiovascular System, Geiger SV (ed) pp 41 – 101 Baltimore: American Physiology Society
- Strahler AN (1957) Quantitative analysis of watershed geomorphology. Trans Am Geophys Union 38: 913–920
- Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21–38
- Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626–1634
- Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413–6422
- Wiedeman MP (1984) Architecture. In Handbook of Physiology Section 2: Cardiovascular System, Geiger SV (ed) pp 11 – 40. Baltimore: American Physiology Society
- Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L (1982) Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159–164
- Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1–10
- Yamaura H, Sato H (1974) Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 53: 1229–1240
- Zhao S, Moore JV, Waller ML, McGown AT, Hadfield JA, Pettit GR, Hastings DL (1999) Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med 26: 231–238
Source: PubMed